Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
AddLife AB (publ) (ALIF-B.ST)
Stockholm, SE
AddLife AB (publ), a company established in 1906 and headquartered in Stockholm, Sweden, specializes in delivering cutting-edge equipment, medical apparatus, and chemical reagents. Its primary clientele includes the healthcare sector, academic and research organizations (such as colleges and universities), and key players within the food and pharmaceutical industries. The firm's operations are divided into two distinct divisions: Labtech and Medtech. The Labtech segment provides a comprehensive array of products, integrated solutions, and expert services, focusing on diagnostics, biomedical research, and general laboratory requirements. This encompasses specialized instruments for areas like haematology, pathology, immediate diagnostic testing (point-of-care), cell biology, genetics, microbiology, virology, molecular biology, clinical chemistry, immunology, along with consumables and advanced analytical machinery. This division further offers vital support, maintenance, consultancy, and educational programs. Conversely, the Medtech segment concentrates on supplying a wide range of medical devices tailored for critical applications such as surgical procedures, respiratory support, intensive care, wound management, and enteral nutrition. It also develops products for fall prevention, welfare technology, and ear, nose, and throat conditions, in addition to offering specific assistive devices for bathrooms and specialized aids for children with disabilities. AddLife maintains a broad international presence, conducting business in its home country of Sweden, across the Nordics (Finland, Denmark, Norway), the United Kingdom, Ireland, Germany, Italy, Austria, Switzerland, other parts of Europe, and globally.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.12% | -1.59% | +4.20% | -3.44% | -21.22% | -1.78% | -19.25% | +11.95% | -40.44% | +500.16% | +526.95% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+1.5% Q1'26: -2.1% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+122.2% ★ Q1'26: +6.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+11.0% ★ Q1'26: +3.9% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+9.5% Q1'26: +8.7% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+7.7% ★ Q1'26: +6.6% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×2.65× Q1'26: 5.26× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2016 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.56B
est: 2.02B (-22.5%)
|
1.94B
est: 2.02B (-3.8%)
|
2.33B
est: 2.41B (-3.3%)
|
2.48B
est: 2.58B (-3.7%)
|
3.48B
est: 2.71B (+28.6%)
|
7.99B
est: 8.20B (-2.5%)
|
9.08B
est: 8.91B (+2.0%)
|
9.69B
est: 9.99B (-3.0%)
|
10.29B
est: 10.14B (+1.4%)
|
10.44B
est: 10.47B (-0.3%)
|
10.78B
10.78B – 10.78B
+2.9% YoY
|
11.49B
11.49B – 11.49B
+6.6% YoY
|
12.21B
12.19B – 12.23B
+6.3% YoY
|
12.66B
12.66B – 12.66B
+3.7% YoY
|
| EBITDA |
150.30M
est: 334.20M (-55.0%)
|
206.70M
est: 334.20M (-38.2%)
|
254.40M
est: 399.95M (-36.4%)
|
264.80M
est: 427.47M (-38.1%)
|
428.00M
est: 448.70M (-4.6%)
|
1.46B
est: 1.36B (+7.8%)
|
1.45B
est: 1.48B (-1.8%)
|
1.53B
est: 1.64B (-6.5%)
|
1.52B
est: 1.67B (-8.9%)
|
1.80B
est: 1.72B (+4.7%)
|
1.77B
1.77B – 1.77B
+2.9% YoY
|
1.89B
1.89B – 1.89B
+6.6% YoY
|
2.01B
2.00B – 2.01B
+6.3% YoY
|
2.08B
2.08B – 2.08B
+3.7% YoY
|
| EBIT |
106.80M
est: 187.00M (-42.9%)
|
141.10M
est: 187.00M (-24.5%)
|
165.60M
est: 223.79M (-26.0%)
|
165.20M
est: 239.19M (-30.9%)
|
194.70M
est: 251.07M (-22.5%)
|
986.20M
est: 760.42M (+29.7%)
|
728.00M
est: 826.42M (-11.9%)
|
615.00M
est: 860.21M (-28.5%)
|
705.00M
est: 873.50M (-19.3%)
|
993.00M
est: 902.21M (+10.1%)
|
928.82M
928.82M – 928.82M
+2.9% YoY
|
989.77M
989.77M – 989.77M
+6.6% YoY
|
1.05B
1.05B – 1.05B
+6.3% YoY
|
1.09B
1.09B – 1.09B
+3.7% YoY
|
| Net Income |
77.80M
est: 131.51M (-40.8%)
|
111.80M
est: 131.51M (-15.0%)
|
120.30M
est: 200.09M (-39.9%)
|
129.30M
est: 220.39M (-41.3%)
|
140.60M
est: 231.99M (-39.4%)
|
719.00M
est: 744.99M (-3.5%)
|
480.00M
est: 789.07M (-39.2%)
|
190.00M
est: 118.00M (+61.0%)
|
252.00M
est: 620.29M (-59.4%)
|
560.00M
est: 805.12M (-30.4%)
|
713.31M
713.31M – 713.31M
-11.4% YoY
|
835.99M
835.99M – 835.99M
+17.2% YoY
|
931.85M
931.85M – 931.85M
+11.5% YoY
|
865.23M
865.23M – 865.23M
-7.1% YoY
|
| SGA |
447.40M
est: 548.95M (-18.5%)
|
528.00M
est: 548.95M (-3.8%)
|
667.10M
est: 656.94M (+1.5%)
|
714.10M
est: 702.16M (+1.7%)
|
1.01B
est: 737.02M (+37.0%)
|
1.87B
est: 2.23B (-16.1%)
|
2.67B
est: 2.43B (+9.9%)
|
3.07B
est: 2.89B (+6.2%)
|
3.08B
est: 2.93B (+5.2%)
|
3.14B
est: 3.03B (+3.7%)
|
3.12B
3.12B – 3.12B
+2.9% YoY
|
3.32B
3.32B – 3.32B
+6.6% YoY
|
3.53B
3.52B – 3.53B
+6.3% YoY
|
3.66B
3.66B – 3.66B
+3.7% YoY
|
| EPS |
0.99
est: 1.08 (-8.3%)
|
1.16
est: 1.08 (+7.5%)
|
1.18
est: 1.64 (-28.1%)
|
1.29
est: 1.81 (-28.7%)
|
1.27
est: 1.90 (-33.3%)
|
6.02
est: 6.11 (-1.5%)
|
3.94
est: 6.48 (-39.2%)
|
1.56
est: 0.97 (+61.1%)
|
2.07
est: 5.09 (-59.3%)
|
4.60
est: 6.61 (-30.4%)
|
5.85
5.85 – 5.85
-11.4% YoY
|
6.86
6.86 – 6.86
+17.2% YoY
|
7.65
7.65 – 7.65
+11.5% YoY
|
7.10
7.10 – 7.10
-7.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | B- | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-26 | B- | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-25 | B- | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-21 | B- | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | B- | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-05 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-04 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-30 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-29 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-28 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-27 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares OMX Stockholm Capped UCITS ETF OM3X.DE | 0.22% | 463.1K | 0.10% |
| 2 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.14% | 483.2K | 0.23% |
| 3 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.14% | 483.2K | 0.23% |
| 4 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.13% | 4.49M | 0.30% |
| 5 | iShares MSCI Europe Small-Cap ETF IEUS | 0.12% | 213.8K | 0.41% |
| 6 | Avantis International Small Cap Equity ETF AVDS | 0.09% | 281.3K | 0.30% |
| 7 | State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR Acc ZPRX.DE | 0.07% | 510.6K | 0.30% |
| 8 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.05% | 122.3K | 0.83% |
| 9 | iShares MSCI EAFE Small-Cap ETF SCZ | 0.05% | 7.37M | 0.40% |
| 10 | Dimensional - International Small Cap ETF DFIS | 0.05% | 2.88M | 0.39% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Fredrik Dalborg | President & Chief Executive Officer | 11M | male |
| Ida Odman Holmqvist | Group Sustainability Controller | — | — |
| Jamilah Wass | Group Financial Controller | — | female |
| Johanna Prim | Group Financial Controller | — | — |
| Julie O'Leary | Investor Relations Manager | — | — |
| Malin Lindh | Group Business Controller | — | — |
| Nichlas Essner | Group Business Controller | — | — |
| Christina Rubenhag | Chief Financial Officer | — | female |
| Timmy Rosendal | Head of Sustainability | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALIF-B.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
